Plain-English translation of NCT07275970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our PTSD research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether psilocybin-containing mushrooms can help treat PTSD (post-traumatic stress disorder). Researchers will give participants a single dose of psilocybin in a chocolate form and carefully monitor how safe it is and whether it helps reduce PTSD symptoms. This medication has shown promise in other research, and this study is one of the first steps in understanding whether it could become a treatment option for people struggling with PTSD.
PTSD can be very difficult to treat, and many people don't respond well to current medications. This medication has shown potential in early research to help people process trauma and reduce PTSD symptoms, so researchers want to test whether it is safe and effective in a controlled study setting.
You will come to the study site on one main day to take a single dose of psilocybin mushrooms mixed into a chocolate formulation. Before and after that dose, you'll have screening visits with blood tests and check-ins with a psychiatrist. Throughout the study, you'll wear a health-tracking device daily and complete questionnaires about your symptoms and quality of life. The study involves careful medical monitoring to ensure your safety, and you'll need to commit to staying off certain other medications and substances during the study period.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Scottsdale Research Institute
Enrollment target
~24 participants
Started
March 2026
Primary completion
July 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.